CC-292

Drug Celgene Corporation
Total Payments
$24,011
Transactions
6
Doctors
1
Companies
1

Payment Trends by Year

Year Amount Transactions Doctors
2019 $9,069 2 0
2018 $1,827 2 1
2017 $13,115 2 0

Payments by Nature

Nature of Payment Amount Transactions Share
Unspecified $24,011 6 100.0%

Research Studies & Clinical Trials

Study Name Sponsor Amount Doctors
CC-292-RA-001 Celgene Corporation $11,200 0
A MULTICENTER, PHASE 1B, OPEN-LABEL STUDY TO DETERMINE THE SAFETY AND ACTIVITY OF CC-292 IN COMBINATION WITH LENALIDOMIDE IN SUBJECTS WITH RELAPSED AND/OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA / SMALL LYMPHOCYTIC LYMPHOMA (CC-292-CLL-001) Celgene Corporation $9,069 0
CC-292-CLL-001 Celgene Corporation $1,915 0
CC-292-RA-001 - A Phase 2a, 4-Week Double-Blind, Proof-of-Concept Efficacy and Safety Study of CC-292 Versus Placebo as Co-therapy with Methotrexate in Active Rheumatoid Arthritis Celgene Corporation $1,156 1
CC-292-CLL-001 - A MULTICENTER, PHASE 1B, OPEN-LABEL STUDY TO DETERMINE THE SAFETY AND ACTIVITY OF CC-292 IN COMBINATION WITH LENALIDOMIDE IN SUBJECTS WITH RELAPSED AND/OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA / SMA Celgene Corporation $671.00 0

Top Doctors Receiving Payments for CC-292

Doctor Specialty Location Total Records
Unknown — Lafayette, IN $22,855 5
, MD Rheumatology Duncansville, PA $1,156 1

Manufacturing Companies

Product Information

  • Type Drug
  • Total Payments $24,011
  • Total Doctors 1
  • Transactions 6

About CC-292

CC-292 is a drug associated with $24,011 in payments to 1 healthcare providers, recorded across 6 transactions in the CMS Open Payments database. The primary manufacturer is Celgene Corporation.

Payment data is available from 2017 to 2019. In 2019, $9,069 was paid across 2 transactions to 0 doctors.

The most common payment nature for CC-292 is "Unspecified" ($24,011, 100.0% of total).

CC-292 is associated with 5 research studies, including "CC-292-RA-001" ($11,200).